VC: Investing preapproval too risky

An interview with med tech VC investor Dave Eichler of Psilos explores the current venture investing landscape in the sector. He said his firm is focused on growth capital for medical device companies and no longer seeks to invest preapproval. Psilos used to invest in early-stage med tech but doesn't any longer since the risk/reward calculation wasn't making sense. The firm also focuses on technology that can lower the cost and improve the quality of healthcare. Molecular breast imaging is of particular interest to Eichler currently. More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.